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Hepatocellular Screening Guidelines and Bellevue’s High Risk Population
Ramoncito David

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the world.1
The prevalence of this fatal disease greatly varies among different nations, due to the fact that almost
80% of cases are secondary to hepatitis B or C.2
The implementation of an effective vaccine against the hepatitis B virus (HBV) has reduced the
prevalence of HBV carriers in North America to 0.1-2%; however, hepatitis B remains a global public
health problem due its high prevalence in Asia and Africa, where 10-20% of the general population are
carriers.3
Hepatitis C in the United States is more prevalent in urban areas with higher populations of
immigrants and intravenous drug users. Bellevue’s patient population is at high risk for hepatocellular
carcinoma because of our many Asian, African, and IV-drug-using patients and our relatively high rates
of hepatitis B and C.
According to the American Association for the Study of Liver Diseases (AASLD), patients at high
risk for developing HCC should be entered into a surveillance program that screens them at regular
intervals to check for new lesions in the liver. By examining current guidelines and looking at how they
are applied at Bellevue, we can shed some light on the question of whether we are screening too many
patients or too few.
The updated AASLD guidelines published in 2010 state that high-risk groups should be screened
with ultrasonography every 6 months.4 Ultrasound as a screening test for HCC has a sensitivity that
ranges from 65% to 80% and a specificity greater than 90%. The main disadvantage of this test is that it
is operator-dependent; hence the wide range in sensitivity.5 In addition, lesions in the liver are more
difficult to detect sonographically in obese and cirrhotic patients, further decreasing the sensitivity.
However, due to its cost-effectiveness, safety, and efficacy, ultrasonography is the preferred HCC
screening and surveillance modality.
Alpha-fetoprotein (AFP) is a serum marker that can be elevated in patients with primary liver cancer. The optimal threshold for elevated AFP levels in HCC screening tests was found to be 20 ng/mL,
but even then a screening test employing this cut-off would have a sensitivity of only 60% and a positive
predictive value of only 41.5% when the prevalence of HCC is assumed to be 5%, as seen in most liver
clinics.6 Some institutions use a combination of ultrasonography and AFP levels for screening, which
results in increased sensitivity at the cost of a higher false positive rate.7 However, screening with AFP
alone is not recommended, since it was shown in the Hepatitis C Antiviral Long-term Treatment Against
Cirrhosis (HALT-C) Trial to be ineffective.8 Interestingly, studies imply that AFP is even less sensitive
for the diagnosis of HCC in African-Americans with cirrhosis due to hepatitis C.9
Some have suggested triple-phase CT scanning or MRI as alternative imaging options, but their use
has not been studied in non-biased populations where there has not already been suspicion for HCC.10
Moreover, given that the suggested interval time for screening is 6 months, CT scanning would expose
the patient to high levels of radiation. Serial MRIs and triple-phase CTs would also accrue significant
costs. However, given the availability of resources at some institutions and the lack of contrastenhanced ultrasonography in the United States11, CT scanning may be the best option for screening since
it has been shown to have high sensitivity for finding lesions and is not as user-dependent as
ultrasonography. At Bellevue, surveillance for HCC in at-risk patients is done by CT scan or MRI every
6 months, which is typically the length of time it takes for tumor size to double.
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Limiting screening to high-risk patients makes sense because of the potential harm involved: false
positives can lead to further unnecessary testing and IV contrast can harm patients with renal
insufficiency. The many risk factors for developing HCC include race, male gender, hepatitis B carrier
state, chronic hepatitis C infection, hereditary hemochromatosis, cirrhosis, non-alcoholic fatty liver disease, diabetes, alpha-1-antitrypsin deficiency, exposure to environmental toxins (aflatoxin, contaminated
drinking water), smoking, and alcohol abuse.12-15 For non-cirrhotic hepatitis B patients, the AASLD
guidelines suggest screening all Asian males over the age of 40, Asian females over the age of 50,
patients with a positive family history of HCC, and Africans over the age of 20, regardless of carrier status or viral load. They also recommend screening all patients with cirrhosis of any etiology.16
Using the subset of Asian HBV carriers as a study group, we can look more closely at the impact
that screening has on mortality. A 2004 trial based in Shanghai, randomized 18,816 Chinese patients
between the ages of 35 to 59 with chronic hepatitis B to an active surveillance group followed with an
AFP level and ultrasound every 6 months or to an observation group to be followed for up to 20 years.
After 5 years they found that mortality due to HCC was significantly lower in the surveillance group
compared to the observation group (83 per 100,000 vs. 132 per 100,000, mortality rate ratio 0.63, 95%
CI 0.41-0.98).17 The 37% decrease in mortality was attributed to detection of the lesions at an earlier
stage in the surveillance group. The number needed to treat (NNT) for this sample was 2,041. Since the
treatment offered in the study was resection, it is important to note that in the setting of chronic hepatitis
B, HCC may arise prior to the development of cirrhosis, thus improving the prognosis for non-cirrhotic
patients undergoing resection.
Given the demonstrated benefit of early detection of HCC through screening, it is important to examine whether we healthcare providers are using screening to its full potential. Cost-effectiveness is
one way to assess this, and it is generally accepted that surveillance is cost-effective in cirrhotics who
have an expected annual incidence of HCC greater than 1.5% per year. Since the incidence of HCC in
cirrhotic liver disease of any etiology typically ranges from 3% to 8% per year, it is clear that screening
for these high-risk groups is cost-effective and potentially life-saving, given the high mortality rate
associated with HCC.18,19
In terms of the actual costs of screening tests, one study performed a cost-utility analysis comparing
the incremental costs of four of the most commonly used screening modalities vs. no screening: AFP
level alone, abdominal ultrasound and AFP, abdominal triple-phase CT and AFP, and abdominal MRI
and AFP. Utilizing Medicare reimbursement data as a standard of cost, they found that screening with
ultrasonography and AFP level had an incremental cost-utility ratio of $26,689 per quality-adjusted life
year, while abdominal CT and AFP was associated with an incremental cost-utility ratio of $25,232 per
quality-adjusted life year. AFP alone is not a viable option due to lack of efficacy, and MRI with AFP
had a significantly higher cost-utility ratio of $118,000 per quality-adjusted life year.20 According to this
data, abdominal CT with AFP level appears to be the most cost-effective screening modality. More
inclusive criteria for screening with CT and AFP would inevitably result in a marginal increase in financial burden, with the incremental costs being dependent on the number of new patients meeting the revised criteria.
Before considering a change in the criteria for screening, it is important to evaluate how well the
current guidelines work when implemented at a hospital with a high volume of at-risk patients. Here at
Bellevue we see many patients with chronic hepatitis B, most of whom are immigrants from China who
likely acquired the viral infection by vertical transmission during birth. These patients have had a longer
course of infection compared to patients who acquired HBV at a later age. They can develop HCC
earlier in their lives, prior to reaching the age at which screening is recommended according to the
AASLD guidelines. When there is no family history and no clinical finding of cirrhosis prompting us to
screen these patients, they are often not diagnosed unless the lesion is found incidentally or the disease
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reaches an advanced stage and becomes symptomatic. Ironically, these young patients with non-cirrhotic
livers are also the ones who would benefit most from early detection and subsequent resection.
Unfortunately, they are not usually screened since they do not meet the criteria under the current
guidelines. Thus it would be helpful to establish more sensitive criteria for identifying patients who are
at higher risk for developing early onset hepatocellular carcinoma. One study has shown that in young
HBV patients, smoking and cirrhosis were significant risk factors for developing HCC.21 In order for
clinicians to implement the tool of screening in a more cost-effective and efficacious manner, further
studies need to be done to elucidate important risk factors such as those that can be incorporated into a
targeted algorithm for screening that includes those patients at highest risk for developing HCC at a
young age.
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